(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 133.07% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.3%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Nyxoah Sa's revenue in 2025 is $5,736,046.On average, 11 Wall Street analysts forecast NYXH's revenue for 2025 to be $314,159,891, with the lowest NYXH revenue forecast at $226,261,008, and the highest NYXH revenue forecast at $404,866,447. On average, 11 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,319,756,053, with the lowest NYXH revenue forecast at $801,272,439, and the highest NYXH revenue forecast at $1,894,355,691.
In 2027, NYXH is forecast to generate $2,805,089,941 in revenue, with the lowest revenue forecast at $2,274,589,486 and the highest revenue forecast at $3,202,581,566.